JMP Securities Reiterates Market Outperform Rating for Jasper Therapeutics (NASDAQ:JSPR)

JMP Securities reissued their market outperform rating on shares of Jasper Therapeutics (NASDAQ:JSPR) in a report issued on Tuesday morning, Benzinga reports. They currently have a $70.00 target price on the stock.

JSPR has been the subject of a number of other reports. Stifel Nicolaus started coverage on shares of Jasper Therapeutics in a research report on Thursday, June 27th. They set a “buy” rating and a $86.00 price target for the company. BTIG Research started coverage on Jasper Therapeutics in a research report on Monday, July 8th. They issued a “buy” rating and a $90.00 target price on the stock. Evercore ISI restated an “outperform” rating and set a $65.00 price target on shares of Jasper Therapeutics in a research report on Monday, August 26th. HC Wainwright reiterated a “buy” rating and issued a $65.00 price objective on shares of Jasper Therapeutics in a report on Tuesday. Finally, Royal Bank of Canada lowered their target price on Jasper Therapeutics from $70.00 to $68.00 and set an “outperform” rating for the company in a report on Wednesday, August 14th. Ten equities research analysts have rated the stock with a buy rating, According to MarketBeat, Jasper Therapeutics presently has an average rating of “Buy” and an average target price of $74.86.

Jasper Therapeutics Stock Performance

Shares of Jasper Therapeutics stock opened at $20.04 on Tuesday. Jasper Therapeutics has a fifty-two week low of $4.00 and a fifty-two week high of $31.01. The firm has a market capitalization of $301.88 million, a price-to-earnings ratio of -3.56 and a beta of 2.21. The stock has a 50 day moving average of $19.11 and a 200 day moving average of $21.48.

Jasper Therapeutics (NASDAQ:JSPR) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.12. Analysts forecast that Jasper Therapeutics will post -4.16 EPS for the current year.

Institutional Investors Weigh In On Jasper Therapeutics

Several large investors have recently bought and sold shares of the stock. American Century Companies Inc. boosted its stake in shares of Jasper Therapeutics by 27.1% in the 2nd quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock valued at $322,000 after buying an additional 3,032 shares during the period. Wolff Wiese Magana LLC acquired a new position in Jasper Therapeutics during the 3rd quarter worth approximately $59,000. Virtu Financial LLC purchased a new stake in shares of Jasper Therapeutics in the 1st quarter valued at approximately $306,000. Rhumbline Advisers acquired a new stake in shares of Jasper Therapeutics in the 2nd quarter valued at $300,000. Finally, Concurrent Investment Advisors LLC purchased a new stake in shares of Jasper Therapeutics during the 1st quarter worth $599,000. Hedge funds and other institutional investors own 79.85% of the company’s stock.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.